Ascendis Pharma

Latest news

• Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026 (opens in a new tab)

  TradingView · Sep 30, 2026

• Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today (opens in a new tab)

  Benzinga · Sep 30, 2026

• BioMarin and Ascendis Pharma Finalize Settlement and Licensing Agreement for Navepegritide (opens in a new tab)

  Kalkine Media · Sep 30, 2026

• BioMarin Licenses CNP IP to Ascendis; 20% US, 18% EU/Brazil/S. Korea Royalties Until May 2030 (opens in a new tab)

  TradingView · Sep 30, 2026

• Ascendis Pharma Closes Warrant Exercise Window, Lifts Share Capital on September 29, 2026 (opens in a new tab)

  tipranks.com · Sep 29, 2026

• Form 4 Ascendis Pharma A/S For: 29 September By Investing.com (opens in a new tab)

  Investing.com Nigeria · Sep 29, 2026

• Ascendis Pharma Sinks After Novo Nordisk Exit Shock (opens in a new tab)

  tipranks.com · Sep 29, 2026

• ASND Price Today: Ascendis Pharma A/S Stock Price, Quote & Chart | MEXC (opens in a new tab)

  MEXC · Sep 29, 2026

• Ascendis Pharma (ASND) Climbs to $230.05 as Shares Push Toward Upper Range - SuperTrend (opens in a new tab)

  siam.in · Sep 28, 2026

• Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $273 (opens in a new tab)

  Moomoo · Sep 28, 2026

• Ascendis Pharma Price Target Maintained With a $300.00/Share by Cantor Fitzgerald (opens in a new tab)

  Moomoo · Sep 28, 2026

• Ascendis Pharma (ASND) Could Be 28% Undervalued As It Reclaims TransCon Rights (opens in a new tab)

  Simply Wall Street · Sep 26, 2026

• Ascendis Pharma Falls as Investors Reassess Novo Rights Reversion and Pipeline Execution Risk (opens in a new tab)

  Quiver Quantitative · Sep 23, 2026

• Ascendis Pharma Sinks As Novo Deal Collapse Spooks Wall Street (opens in a new tab)

  tipranks.com · Sep 23, 2026

• Ascendis Pharma (ASND) Authorizes $400M Share Buyback (opens in a new tab)

  Yahoo Finance · Sep 20, 2026

• Ascendis Pharma (ASND) Stock Looks Near Fair Value On Infant Trial Data (opens in a new tab)

  Simply Wall Street · Sep 18, 2026

• Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost? (opens in a new tab)

  Yahoo Finance · Sep 17, 2026

• Ascendis Pharma: Back To Full Independence (NASDAQ:ASND) (opens in a new tab)

  Seeking Alpha · Sep 16, 2026

• Ascendis Pharma (ASND) Reclaims Global TransCon Rights For Obesity And Heart Disease (opens in a new tab)

  Simply Wall Street · Sep 16, 2026

• Ascendis regains obesity rights as Novo exits monthly GLP-1 deal (opens in a new tab)

  The Pharma Letter · Sep 16, 2026

• H.C. Wainwright reiterates Ascendis Pharma stock rating on Novo deal end (opens in a new tab)

  Investing.com · Sep 16, 2026

• Why Is Ascendis Pharma Stock Trading Lower on Tuesday? (opens in a new tab)

  TradingView · Sep 15, 2026

• Raymond James downgrades Ascendis Pharma stock rating on partnership shift (opens in a new tab)

  Investing.com · Sep 15, 2026

• Ascendis Pharma Slides as Investors Weigh Novo Rights Reversion Despite Buyback (opens in a new tab)

  Quiver Quantitative · Sep 15, 2026

• Ascendis Pharma at Morgan Stanley conference: cash flow, growth and rights (opens in a new tab)

  Investing.com · Sep 15, 2026

• Raymond James Downgrades Ascendis Pharma to Outperform From Strong Buy (opens in a new tab)

  Yahoo Finance · Sep 15, 2026

• Ascendis Pharma Regains Rights to Obesity Drug, Discloses $400 Million Share Buyback (opens in a new tab)

  Yahoo Finance · Sep 15, 2026

• Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis (opens in a new tab)

  Fierce Biotech · Sep 15, 2026

• Ascendis Pharma (NASDAQ: ASND) board okays discretionary $400M share buyback (opens in a new tab)

  Stock Titan · Sep 15, 2026

• Ascendis Pharma gains full rights to TransCon t... (opens in a new tab)

  Pluang · Sep 15, 2026